See Detailed Description
Phase II Multicentre, Randomised, Double-Blind, Placebo and Active-Controlled, Dose-Ranging,
Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor
Antagonist, GW679769 in Combination with Ondansetron Hydrochloride and Dexamethasone for the
Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly
Emetogenic Cisplatin-based Chemotherapy.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
The number of subjects who do not experience vomiting, retching or nausea over a 5 day period following the initiation of chemotherapy.
GSK Clinical Trials, MD
Italy: The Italian Medicines Agency